Decision-Makers Agree—Phase I Clinical Research is Becoming More Complex

Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. — October 16, 2018 — Industry Standard Research (ISR) announces the release of its newest report, “Phase I Study Trends and Market Outlook (2018-2022),” in which 143 Phase I decision-makers provide valuable insight into market size, factors that could affect the number of studies conducted … Continued

Biotrial and SGS Life Sciences Receive High Marks for Accessibility

Informing pharmaceutical drug developers, manufacturers, and service providers Raleigh, N.C. – September 27, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase I Service Providers series. ISR surveyed 305 decision-makers at sponsor organizations to gather their insights on topics such as service provider … Continued

CRO Growth Continues, ISR Projects More Growth to Come

Informing the drug development and pharmaceutical manufacturing industry. Raleigh, N.C. – September 25, 2018 – Industry Standard Research (ISR) has announced the newest edition of its CRO market analysis report “2018 CRO Market Size Projections: 2017-2022.” For this report, ISR has utilized publicly available information from biopharma, government, private, non-profit, and academic institutions as well as … Continued

Large CROs Stand Out in Post-marketing Pharmacovigilance

Informing pharmaceutical drug developers, manufacturers, and service providers. Raleigh, N.C. – September 24, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase IV Service Providers series. ISR surveyed 230 decision-makers at sponsor organizations to gather their insights on topics such as service provider brand perceptions and use, … Continued

Big Pharma CMOs win for Biologic API and Alcami Scores Highest for Biologic Drug Product

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Raleigh, NC – May 23, 2018 –Industry Standard Research’s (ISR’s) 3rd annual Biologic API Contract Manufacturer Quality Benchmarking report shows Big Pharma CMOs—AbbVie Contract Manufacturing, Boehringer Ingelheim, and CEPiA Sanofi—received the highest Overall Performance Scores for drug substance manufacturing. Also just released, ISR’s Biologic Drug Product … Continued

Accenture and Medpace Excel in Phase II/III Delivery Factors

Informing pharmaceutical drug developers, manufacturers, and service providers. Raleigh, N.C. – May 17, 2018 – Industry Standard Research (ISR) has released a new report, the 10th edition of its CRO Quality Benchmarking – Phase II/III Service Providers series. ISR surveyed 301 decision-makers at sponsor organizations to gather their insights on topics such as service provider … Continued

FLAMMA, Novasep and Alcami Win for Small Molecule Contract Manufacturing Performance

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – May 15, 2018 –  Industry Standard Research’s (ISR’s) annual Small Molecule API Contract Manufacturer Quality Benchmarking report reveals that FLAMMA and Novasep received the highest Overall Performance Scores based on customer expectations. The Small Molecule Drug Product Contract Manufacturer Quality Benchmarking report, also just … Continued

Is CRO Consolidation Good For Pharma?

Consolidation continues in the CRO space, with the acquisition of Chiltern by LabCorp being just the latest example of top CROs expanding and increasing their breadth of offerings. As large CROs continue to acquire smaller competitors, can sponsor companies expect to benefit from this development? I recently spoke to Andrew Schafer, president of research firm … Continued

Respondents Average 3.2 Small Molecule Sterile Injectables in Their Development Pipelines

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – August 8, 2017 –  Industry Standard Research’s (ISR’s) Small Molecule Sterile Injectable Drug Product Manufacturing Market Overview and Outlook report looks specifically at the portfolios and pipelines of small molecule sterile injectable outsourcers to gauge future demand among outsourcers, to understand how contract manufacturers are selected … Continued

Low cost continues to gain importance among both development and commercial small molecule outsourcers

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – July 25, 2017 –  Industry Standard Research’s (ISR’s) Development vs Commercial Outsourced Manufacturing Practices: Small Molecule report offers insight into how the industry, using different outsourcing scenarios, prioritizes CMO selection attributes. Whether selecting a CMO for the first time or for the 50th … Continued

Development-stage drug product outsourcers highly value Right-first-time measurements

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – July 25, 2017 –  Industry Standard Research’s (ISR’s) Development vs Commercial Outsourced Manufacturing Practices: Biologics report offers insight into how respondents in different outsourcing scenarios prioritize different CMO selection attributes. Whether selecting a CMO for the first time or for the 50th time, this … Continued

Traditional Tablets Will Lose Market Share Due to Increased Use of Modified Release Technologies

Informing the pharmaceutical drug development, manufacturing and commercialization industry. CARY, NC – May 31, 2017 – The 2nd edition of Industry Standard Research’s (ISR’s) Oral Dosage Forms Market Overview and Outlook report offers details on how industry utilization rates of seventeen different oral dosage forms will shift over the next five years as new technologies and capabilities … Continued

INC Research, PPD Shine in ISR’s 2017 Phase IV CRO Quality Benchmarking Report

Informing the pharmaceutical drug development, manufacturing and commercialization industry. CARY, NC – May 31, 2017 – Industry Standard Research (ISR) has released a new report, CRO Quality Benchmarking – Phase IV Service Providers (9th Edition), containing findings focused on service provider selection and evaluation. Kevin Olson, CEO, explains, “Each Phase IV clinical outsourcing need is unique. … Continued

Celerion, SGS Life Sciences Stand-out Performers in ISR’s 2017 Phase I Quality Benchmarking Report

Informing the pharmaceutical drug development, manufacturing and commercialization industry. CARY, NC – May 18, 2017 – Industry Standard Research (ISR) has released a new report, CRO Quality Benchmarking – Phase I Service Providers (9th Edition), containing findings focused on service provider selection and evaluation. Kevin Olson, CEO, explains, “While some outsourced Phase I projects may lend themselves to … Continued

Medpace and DCRI-Duke exceed expectations in Phase II/III Staff Characteristics

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, N.C. – April 26, 2017 – Industry Standard Research (ISR) has released a new report, CRO Quality Benchmarking – Phase II/III Service Providers (9th Edition), containing findings focused on service provider selection and evaluation. Kevin Olson, CEO, explains, “This report offers critical information for those … Continued

ISR Projects Strong Growth in the CRO Market

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – March 7, 2017 – Industry Standard Research (ISR) today announced the release of its latest CRO market report titled; 2017 Edition of the CRO Market Size Projections: 2016-2021. This report provides readers with a comprehensive assessment of the global market for CRO services. … Continued

CMOs need to increase awareness of offerings, ISR reports

A “new set of leaders” emerged in the contract manufacturing organization (CMO) industry over the past year, though many remain unheard of, according to a recent report. Kate Hammeke, Vice President, Market Research, Industry Standard Research, told us drug product outsourcers are consistent in their prioritization of CMO selection attributes. “The same three attributes topped … Continued

Big Pharma CMOs capture strongest performance ratings for small molecule API manufacturing

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – February 9, 2017 – The 2nd edition of Industry Standard Research’s (ISR’s) Small Molecule API Contract Manufacturer Quality Benchmarking report reveals that the top performing CMOs relative to expectations, and based off customer feedback on recent service encounters, are contract manufacturers with a drug … Continued

Regulatory history and reliable on-time delivery beat cost and capacity as the most important selection attributes for drug product CMOs

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – February 8, 2017 – The 2nd edition of Industry Standard Research’s (ISR’s) Drug Product Contract Manufacturer Quality Benchmarking report reveals that buyers of outsourced drug product manufacturing services value a strong regulatory history and reliable on-time delivery more than low cost when selecting … Continued

Customer loyalty scores for biologic API contract manufacturers slip

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – February 8, 2017 – The 2nd edition of Industry Standard Research’s (ISR’s) Biologic API Contract Manufacturer Quality Benchmarking report indicates that buyers of outsourced biologic API services are less loyal to the CMOs they use compared to one year ago. The report includes … Continued

Two-thirds of pharmaceutical manufacturing is outsourced, ISR Reports

Only one-third of manufacturing is currently conducted in-house, from development stages to after commercial launch, according a recent report. The report, published by Industry Standard Research (ISR), explained that the majority of work is outsourced – and mainly to preferred providers, who are netting the largest portion of work. According to Kate Hammeke, Vice President … Continued

Two-thirds of pharmaceutical manufacturing is outsourced; preferred providers pick up largest share

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – November 18, 2016 – A new market research report from Industry Standard Research (ISR), Contract Development and Manufacturing Outsourcing Models, reveals the motivations and strategies behind drug innovators’ decision to outsource and how different outsourcing relationships are selected. The report explores how sponsor … Continued

Best Practices in Study Feasibility

Successfully navigating the medical, clinical, logistical and regulatory challenges associated with establishing the feasibility of a clinical trial is not easy. Insights from sponsor organizations, CROs and sites have been compiled in ISR’s Best Practices in Study Feasibility report. A particular area of interest for readers of the report are the techniques and innovations proffered … Continued

eTMF market to grow sizably over next three years, ISR reports

The adoption of eTMF solutions is accelerating – with more than 50% of investigative sites expected to have access to a sponsor/CRO eTMF application within three years. This figure is according to a recent report published by Industry Standard Research (ISR), which assessed eTMF (electronic trial master file) application access to be around 20% today. … Continued

eTMF Market Expected to Grow Considerably Over the Next Three Years

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – October 27, 2016 – Industry Standard Research (ISR) today announced the release of a report titled “eTMF Market and Service Provider Dynamics.” This report is designed to give eTMF software providers, CROs and pharmaceutical companies information on the current and future landscape of … Continued

Cell Line Selection Predicted to Shift to CMOs, Double Digit Increase in Demand for the Service

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – October 12, 2016 – A new report from Industry Standard Research (ISR), Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics, offers an in-depth look into the mammalian and microbial expression system manufacturing capabilities currently required by sponsor organizations for biologics in development … Continued

Sponsors and CROs Agree that Integrating Statistical Modeling and Knowledge of Past Performance into Feasibility Analyses Improves Accuracy of Results

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – August 30, 2016 – A new report, Best Practices in Study Feasibility, from Industry Standard Research (ISR) reveals insights into how to successfully navigate many of the challenges—medical, clinical, logistical and regulatory—associated with establishing the feasibility of a clinical trial. A key area … Continued

Specialized Patient Recruitment Firms Bring More Value to a Trial than Adding Sites

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – August 16, 2016 – A new report from Industry Standard Research (ISR), Best Practices in Patient Recruitment, shows that  Sponsors and CROs agree, hiring a specialized patient recruitment firm is a better value than adding more sites to the study. This is, in … Continued

Spend on HEOR Studies Expected to Grow at 9.7% through 2020

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – July 19, 2016 – Industry Standard Research has released a new report, Late Phase Study Trends and Market Outlook (2016-2020), containing findings focused on current dynamics in the Late Phase market and a forecast of how the market will evolve by 2020. “Late … Continued

New ISR Report Reveals Current and Future Dynamics in Phase II/III Market, Changes Expected in Clinical Trial Spend

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – June 21, 2016 – Industry Standard Research has released its comprehensive new report, “Phase II/III Study Trends and Market Outlook (2016-2020),” concerning the trends, resource allocation, and market direction of the pharmaceutical Phase II/III clinical sphere that are expected to take hold in … Continued

One-Third of Cancer Patients Have a Genetic Profile Accessible by Their Oncologist

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – May 24, 2016 – A new market research report titled Personalized Medicine’s Effect on Oncologists’ Treatment Regimens, from Industry Standard Research (ISR), finds that, according to US-based oncologists, currently one-quarter of patients are treated using genetic tumor profiling to inform treatment decisions and … Continued

Two-thirds of Biopharma Sponsors Surveyed Currently Sell or Plan to Sell Biosimilar Products

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – May 17, 2016 – A new report titled Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (3rd edition), from Industry Standard Research (ISR), indicates that the majority of companies with a large molecule offering plan to enter or are already involved in the … Continued

ISR’s New Report Provides Common Structures, Models for Pharma’s Regulatory Affairs Departments

Informing the pharmaceutical drug development, manufacturing and commercialization industry. Cary, NC – March 29, 2016 – Industry Standard Research (ISR) today announced a new addition to its Department Models and Structures suite of reports.  The new report aims to provide readers with a comprehensive assessment of the organizational environment and landscape of Regulatory Affairs departments … Continued

ISR’s Contract Research Quality Benchmarking Reports Are Now Available

Informing the pharmaceutical drug development, manufacturing and commercialization industry Cary, NC – March 15, 2016 – Industry Standard Research (ISR) today announced the release of its annual CRO Quality Benchmarking series of reports.  These three reports outline in detail the delivery quality of dozens of large, mid-size, and niche CROs for Phase I, Phase II/III … Continued

Clinical Outsourcing Market To See Continued Growth Through 2020

You often hear that this is a good time to be in the pharma industry.  I think that is especially true of the clinical trial sector.  Despite the onslaught of bad press pharma is receiving by both politicians and the general public, advancements in oncology and other serious diseases, coupled with the focus on precision … Continued

Fewer European Prescribers Trust Information Received from Telephone Details than Web-based, In-person Details according to ISR’s New Report

Informing the pharmaceutical drug development, manufacturing and commercialization industry Cary, NC – February 23, 2016 – Industry Standard Research (ISR) today announced the release of their “Electronic Detailing in Europe: Value and Outcomes” report.  With this report, ISR investigates the changing nature of European pharmaceutical companies’ sales detailing.  While the pharmaceutical sales detail remains a … Continued

ISR Projects Continued Growth Propelling the CRO Market Forward

Informing the pharmaceutical drug development, manufacturing and commercialization industry Cary, NC – February 2, 2016 – Industry Standard Research (ISR) today announced a new addition to its Market Analysis suite of reports.  The “2016 Edition of the CRO Market Size Projections: 2015-2020” report provides readers with a comprehensive assessment of the global market for CRO … Continued

When are CMOs used? ISR Reports

While CMOs are currently engaged mainly through tactical outsourcing, this paradigm will shift as more companies begin outsourcing to preferred providers, says ISR report. https://www.outsourcing-pharma.com/Contract-Manufacturing/When-are-CMOs-used-ISR-reports

ISR’s Clinical Outsourcing Department Models and Structures Report Is Now Available

Informing the pharmaceutical drug development, manufacturing and commercialization industry Cary, NC – January 27, 2016 – Industry Standard Research (ISR) today announced a new addition to its Department Models and Structures suite of reports.  The new report aims to provide readers with a comprehensive assessment of the organizational environment and landscape within clinical development outsourcing … Continued

ISR’s Contract Manufacturer Quality Benchmarking Reports Are Now Available

Cary, NC – January 12, 2016 – Industry Standard Research (ISR) today announced the addition of three reports to its Contract Manufacturer Quality Benchmarking suite of reports to provide readers a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish. As biopharma companies continue … Continued

2016 CMO Leadership Awards to be announced in Life Science Leader’s March 2016 special supplement

Cary, NC – January 1, 2016 –Life Science Leader (lifescienceleader.com) and Industry Standard Research (ISRreports.com) today announced a publisher-market research partnership, where Industry Standard Research (ISR) will serve as the data collection engine behind Life Science Leader’s annual CMO and CRO Leadership Awards as well as assist in the development of unique data-driven content for the Life … Continued

Pharma’s Outsourcing Model Preferences Revealed in ISR’s New Report

Cary, N.C. – November 17, 2015 – Industry Standard Research (ISR) is announcing the availability of a new report titled Clinical Development Outsourcing Models (2nd edition). This report reveals sponsors’ satisfaction and preferences with seven different outsourcing models, their reasons for model selection, and how each model is used.  It also provides insight into how … Continued

Pfizer CentreSource Lands a Top 3 Position Across All 4 CMO Scorecards in ISR’s Latest Contract Manufacturer Quality Benchmarking Report

Cary, N.C. – June 9, 2015 – Industry Standard Research (ISR) today announced the availability of the “Contract Manufacturer Quality Benchmarking (2015)” report, providing a comprehensive assessment of CMO service quality. This report provides a Consumer Reports-style analysis of CMO quality with respondents giving rating assessments for 481 service encounters across 36 contract manufacturers. Each … Continued

Orphan drug boom comes with a steady stream of outsourcing

With the FDA approving a record number of orphan drugs in 2014, sponsors weren’t the only ones to reap profits from their development. https://www.outsourcing-pharma.com/Clinical-Development/Orphan-drug-boom-comes-with-a-steady-stream-of-outsourcing

ISR Projects a 7.4% Compound Annual Growth Rate for the CRO Market through 2019

Informing the drug development and commercialization industry Cary, N.C. – February 11, 2015 – Industry Standard Research (ISR Reports) has announced the availability of a new report titled “2015 Edition of the CRO Market Size Projections: 2012-2019.” For this report, ISR has utilized both publically available information and data obtained through its syndicated primary market … Continued

Triangle CROs adopt innovative methods to recruit clinical trial patients

Companies that help pharmaceutical and biotechnology companies conduct clinical trials are increasingly focused on unclogging what can be a major bottleneck – recruiting sufficient numbers of patients willing to test an experimental drug in a reasonable period of time. The stakes are high for these contract research organizations, or CROs – an industry that is … Continued

MPI Research, BioReliance among top performers in ISR’s inaugural Preclinical CRO Quality Benchmarking Study

Informing the drug development and commercialization industry Cary, N.C. – January 28, 2015 – Industry Standard Research (ISR) has announced the availability of a new report titled, “CRO Quality Benchmarking – Preclinical Service Providers.” This report provides a Consumer Reports-style analysis of 446 service encounters across 42 preclinical CROs. “Each of these preclinical CROs was … Continued

ISR Reports study finds SGS Life Sciences a stand-out Phase I service provider

Informing the drug development and commercialization industry Cary, N.C. – June 11, 2014 – Industry Standard Research (ISR) today announced the release of their “CRO Quality Benchmarking – Phase I Service Providers” report.  This research, based on in-depth surveys collected from 113 pharmaceutical Phase I decision-makers, indicates that SGS Life Sciences out-performs customers’ expectations across … Continued

New ISR Report Provides Insight into Bladder Cancer Market, Clinical Pipeline

Informing the pharmaceutical drug development and commercialization industry Cary, N.C. – April 15, 2014 – Industry Standard Research (ISR) is announcing the release of its latest report entitled “Bladder Cancer: Disease and Pipeline Analysis.”  This report provides an overview of the current and future bladder cancer clinical development market, the activities of the key market … Continued

DCRI Receives Top Customer Loyalty Scores in ISR’s 6th Annual CRO Quality Benchmarking Study

Informing the Pharmaceutical Drug Development and Commercialization Industry. Cary, N.C. – March 19, 2014 – Industry Standard Research (ISR) is announcing the launch of its 6th annual CRO Quality Benchmarking series with today’s release of its “CRO Quality Benchmarking – Phase II/III Service Providers (2014)” report. This report provides a Consumer Reports-style analysis of CRO quality with respondents … Continued

New ISR Report Provides Insight into CMO Service Quality, DSM among the Top 3 in Each Attribute Category

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – March 12, 2014 – Industry Standard Research (ISR) today announced the availability of a new report titled “Contract Manufacturer Quality Benchmarking (2014),” providing a comprehensive assessment of CMO service quality. “ISR has a long history of measuring service provider quality across the clinical development … Continued

ISR Identifies Patterns of Unmet Needs amongst US Patients Suffering from Headaches

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – March 5, 2013 – Industry Standard Research (ISR) has announced the release of a new market research report titled “Headaches: Current Treatments, Unmet Needs, and Patient Recruitment.” This report surveyed 209 US-based patients who suffer from chronic cluster headaches, tension headaches, or migraines to … Continued

New ISR Report Identifies why Forest Labs’ Pipeline is a Hot Topic

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – February 25, 2014 – Industry Standard Research (ISR) has announced the availability of a new report titled “Forest Labs Clinical Development Profile.”  This report provides a thorough analysis of Forest Laboratories’ R&D pipeline, clinical trial activity, patents, FDA submissions, and includes profiles of Forest’s … Continued

New ISR Report Uncovers Significant Clinical Development Activity, Opportunity in Brazilian Market

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – February 20, 2014 – Industry Standard Research (ISR) released a new market research report this week entitled “Brazil: Clinical Development Country Profile.” The report provides insight into the clinical trial environment in Brazil, sponsor and service provider activities in the region, as well as the Brazilian … Continued

ISR’s Brain Cancer (Glioblastoma Multiforme) Report Analyzes Market Opportunity, Product Pipelines

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – February 19, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis,” offering the biopharmaceutical industry an in-depth overview of the current glioblastoma multiforme (GBM) market and an analysis … Continued

ISR Projects the 2014 CRO Market to be Worth $23.6 Billion

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – February 4, 2014 – Industry Standard Research (ISR) has announced the availability of a new report titled “2014 CRO Market Size Projections: 2012-2018.”  For this report, ISR has utilized both publically available information and data obtained through their syndicated primary market research to provide … Continued

CRO Market Size: Growth in a Flat R&D World

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: CRO Market Size: Growth in a Flat R&D World https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Blogs/CRO-Market-Size-Growth-in-a-Flat-RampD-World/ArticleStandard/Article/detail/834426

ISR Identifies Patterns of Unmet Needs amongst Autoimmune Disease Patients

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – January 7, 2013 – Industry Standard Research (ISR) has announced the release of a new market research report entitled “Autoimmune Diseases: Current Treatments, Unmet Needs, and Patient Recruitment.” This report surveyed 208 US-based patients with an autoimmune disease to identify patterns and preferences surrounding … Continued

United Biosource Corporation (UBC) Receives High Marks for Staff Quality According to ISR Report

Informing the pharmaceutical drug development and commercialization industry. Cary, N.C. – January 6, 2013 – Industry Standard Research (ISR) has announced the availability of a new report titled “2013 CRO Quality Benchmarking – Phase IV Service Providers.”  This study surveyed 106 pharmaceutical and biotechnology professionals about their experiences with 27 small, mid-size, and large Phase … Continued

New ISR Report Offers Visibility into CRO Service Quality for Phase I Clinical Trials

Informing the drug development and commercialization industry Cary, N.C. – August 23, 2013 – Industry Standard Research (ISR) today announced the availability of a new report titled “2013 CRO Quality Benchmarking – Phase I Service Providers” providing the most comprehensive assessment of Phase I clinical research organization (CRO) service quality ever released. “ISR’s report provides … Continued

New ISR Report: Enhancing Relationships, Patient Recruitment with Patient Advocacy Groups

Informing the drug development and commercialization industry Cary, N.C. – July 26, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “Advocacy Groups: Enhancing Relationships and Patient Recruitment.” For the report, ISR interviewed senior decision-makers from ten prominent patient advocacy groups to provide never before seen qualitative … Continued

ISR Report: Expecting Growth in Demand for Bioanalytical Lab Services through 2015

Informing the drug development and commercialization industry Cary, N.C. – July 17, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “Bioanalytical Labs: Market Dynamics and Service Provider Performance.” The report provides the underserved industry with valuable market insights into the current and future demand for bioanalytical … Continued

New ISR Report Uncovers Significant Clinical Development Activity, Opportunity in South Korean Market

Informing the drug development and commercialization industry Cary, N.C. – June 27, 2013 – Industry Standard Research (ISR) released a new market research report this week entitled “South Korea: Clinical Development Country Profile.” The report provides insight into the clinical trial environment in South Korea, sponsor and service provider activities in the region, as well … Continued

ISR Reviews Report “Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing”

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: ISR Reviews Report “Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Blogs/ISR-Reviews-Report-Risk-based-Monitoring-Industry-/ArticleStandard/Article/detail/816364

ISR Reports: Significant Opportunity Remains for Optimizing Clinical Trials by Using Electronic Medical Records

Informing the drug development and commercialization industry Cary, N.C. – June 20, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “EMRs and Clinical Research: Current and Potential Impact.” This report provides the pharmaceutical industry and its service providers with novel insights into the current and future … Continued

ISR’s Liver Cancer Market Report Shows Opportunity for Innovative Sponsors

Informing the drug development and commercialization industry Cary, N.C. – June 6, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “Liver Cancer: Disease and Pipeline Analysis,” providing the pharmaceutical industry with a therapeutic assessment, pipeline analysis, and unique insight into the current clinical trial environment for … Continued

New ISR Phase I Report Shows Rise in Study Complexity and Use of Patient Populations

Informing the drug development and commercialization industry Cary, N.C. – May 15, 2012 – Industry Standard Research (ISR) today announced the release of a new market research report titled “2013 Phase I Study Trends and Market Outlook” providing the pharmaceutical industry and its service providers with new insights into phase-specific trends affecting in-house and outsourced … Continued

ISR’s Risk-based Monitoring Report Offers Industry Peer-based Guidance

Informing the drug development and commercialization industry Cary, N.C. – May 9, 2013 – Industry Standard Research (ISR) released a new market research report today entitled “Risk-based Monitoring: Industry Guidance on Adoption, Use, and Outsourcing.” The report was developed by surveying industry professionals with direct risk-based monitoring (RBM) experience and provides the pharmaceutical industry and … Continued

ISR’s CRO Quality Benchmarking Study Reports DCRI Staff among the Top

Informing the drug development and commercialization industry Cary, N.C. – April 23, 2012 – Industry Standard Research (ISR) announced the launch of its 5th annual CRO Quality Benchmarking series with today’s release of its “2013 CRO Quality Benchmarking – Phase II/III Service Providers” report.  The new study surveyed 157 pharmaceutical and biotechnology professionals about their … Continued

ISR Report Provides Medical Device Industry with Analysis of Historical Trials, Development Market Size, and Manufacturer Profiles

Informing the drug development and commercialization industry Cary, N.C. – April 3, 2013 – Industry Standard Research (ISR) announced the release of a new market research report entitled “Medical Device: Clinical Development Market Assessment,” which provides the medical device industry and its service providers with a new resource for their clinical development activities. “The medical … Continued

What Does the Future Hold for Clinical Monitoring?

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “What Does the Future Hold for Clinical Monitoring?” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=810203

ISR Report Provides Insight into Pancreatic Cancer, Clinical Development Pipeline

Informing the drug development and commercialization industry Cary, N.C. – March 27, 2013 – Industry Standard Research (ISR) today announced the release of a new pharmaceutical market research report entitled “Pancreatic Cancer: Disease and Pipeline Analysis” which provides insight into a market with few effective therapies. “ISR’s latest report profiles the pancreatic cancer market because … Continued

ISR Reports Breaks Down: 2013 Late Phase Market Overview and Outlook

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “ISR Reports Breaks Down: 2013 Late Phase Market Overview and Outlook” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Blogs/ISR-Reports-Breaks-Down-2013-Late-Phase-Market-Ove/ArticleStandard/Article/detail/807543

Influence of Cost in the CRO Selection Process

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Influence of Cost in the CRO Selection Process” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Influence-of-Cost-in-the-CRO-Selection-Process/ArticleStandard/Article/detail/808507

ISR Report Shows Late Phase Study Conduct, Outsourcing Continues to Rise

Informing the drug development and commercialization industry Cary, N.C. – February 20, 2013 – Industry Standard Research (ISR) today announced the release of a new market report titled “2013 Late Phase Market Overview and Outlook” which provides the pharmaceutical industry and its service providers with new insights into this rapidly growing segment of clinical trials. … Continued

ISR’s “Social Media: Best Practices and Strategic Use in Patient Recruitment”

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “ISR’s ‘Social Media: Best Practices and Strategic Use in Patient Recruitment’?” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Blogs/ISRs-Social-Media-Best-Practices-and-Strategic-Use/ArticleStandard/Article/detail/802212

ISR’s Report Offers Social Media Best Practices for Clinical Trial Patient Recruitment

Informing the drug development and commercialization industry. Cary, N.C. – January 8, 2013 – Industry Standard Research (ISR) today announced the release of a new market research report titled “Social Media: Best Practices and Strategic Use in Patient Recruitment,” which will provide the pharmaceutical sponsors and patient recruitment service providers with new insights into the … Continued

Benchmarking Investigator Payments

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Benchmarking Investigator Payments” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=799327

ISR’s New Report Shows eDetailing Fills Void Left by Reduced Rep Presence in Europe

Informing the drug development and commercialization industry. Cary, N.C. – December 5, 2012 – Industry Standard Research (ISR) today launched a new market research report titled “Adoption and Use of eDetailing vs. In-person Detailing in Europe,” providing pharmaceutical manufacturers with new insights into how European physicians prefer to interact with drug makers. “Like in most … Continued

ISR’s Report Analyzes Investigator Payments across 11 Therapeutic Areas

Informing the pharmaceutical and biotech industry. Cary, N.C. – October 30, 2012 – Industry Standard Research (ISR) today announced the availability of their newest report, “Benchmarking Investigator Payments,” which analyzes the level of compensation investigative sites receive for participation in clinical studies. “Investigator payments can account for over 40% of total trial costs, so it … Continued

ISR’s Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies

Informing the pharmaceutical and biotech industry. Cary, N.C. – October 9, 2012 – Industry Standard Research (ISR) today announced the availability of their latest report, “Hepatitis C: Social Media, Search, and Market Analysis,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and … Continued

ISR Reports: Sponsors Indicate a Shift Towards Central Labs in Emerging Markets, Asia

Informing the pharmaceutical and biotech industry. Cary, N.C. – October  2, 2012 – Industry Standard Research (ISR) today announced the availability of their newest clinical development trends report, “Central Lab Market Dynamics and Outsourcing Performance,” which provides an in-depth analysis of topics and trends having an impact on the market for central lab market in … Continued

ISR Reports: Covance Receives Top Ratings in Phase IV Benchmarking Study

Informing the pharmaceutical and biotech industry. Cary, N.C. – September  18, 2012 – Industry Standard Research (ISR) today announced the availability of their newest CRO Benchmarking report, 2012 CRO Quality Benchmarking – Phase IV Service Providers, which provides service quality profiles for 10 Phase IV CROs. “Covance received the highest marks across a number of … Continued

ISR Adds Biosimilar Recruitment to Growing Library of Biosimliar, Recruitment Reports

Informing the pharmaceutical and biotech industry Cary, N.C. – September 11, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled “Improving Patient Recruitment in Biosimilar Trials,” which examines patient and site recruitment in Biosimilar clinical trials. “Teva’s use of a Biologics License Application (BLA) for their regulatory submission and … Continued

Selection of Phase I Service Providers

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Selection of Phase I Service Providers” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Selection-of-Phase-I-Service-Providers/ArticleStandard/Article/detail/788581

Optimizing Investigator Fees

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Optimizing Investigator Fees” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Data+Analysis/Optimizing-Investigator-Fees/ArticleStandard/Article/detail/800011 I’m not sure if it’s just me, but we still have some work to do on the automatically generated e-mails. I’ve provided DETAILED and SPECIFIC instructions I’d like to see … Continued

Access to patient population more important than price for Phase I outsourcing, says ISR

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Access to patient population more important than price for Phase I outsourcing, says ISR” https://www.outsourcing-pharma.com/Clinical-Development/Access-to-patient-population-more-important-than-price-for-Phase-I-outsourcing-says-ISR

Strong Link Between CRO Service Quality and Financial Performance

ISR’s reports have been featured in numerous industry publications and news sources over the years. Below is a link to Appliedclinicaltrialsonline.com’s: “Strong Link Between CRO Service Quality and Financial Performance” https://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=783320

ISR Reports: PPD Receives Top Marks for Customer Loyalty and Value in Phase I

Informing the drug development and commercialization industry Cary, N.C. – July  19, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled 2012 CRO Quality Benchmarking – Phase I Service Providers, which provides service quality profiles for 12 Phase I CROs. “PPD received higher ratings than any other Phase I … Continued

ISR’s Report Provides Novel Data for Oncology MSL and Sales Strategies

Informing the drug development and commercialization industry Cary, N.C. – June 18, 2012 – Industry Standard Research (ISR) today announced the launch of a new market research report titled “MSL and Sales Strategies for the US Oncology Market”, which provides the pharmaceutical and biotech sales and marketing professionals with insight into how US Oncologists want … Continued

ISR’s New Report Uncovers Barriers and Strategies in Investigator Recruitment

Informing the drug development and commercialization industry Cary, N.C. – May 23, 2012 – Industry Standard Research (ISR) today announced the launch of a new market research report titled “Optimizing Investigator Recruitment in Clinical Trials” that provides recruitment professionals with a resource to optimize investigator recruitment and mitigate study delays. ISR’s new report is based … Continued

ISR Profiles the State of Patient Recruitment in Clinical Trials

Informing the drug development and commercialization industry Cary, N.C. – May 2, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled “Optimizing Patient Recruitment in Clinical Trials” that provides sponsors and service providers with valuable insight into the activities and strategies that drive and restrict patient recruitment in clinical … Continued

ISR Study Finds That INC Research Delivers CRO Industry’s Most Consistent Service Quality

Informing the drug development and commercialization industry Cary, N.C. – February 28, 2012 – Industry Standard Research (ISR) today announced the availability of its 4th annual CRO Quality Benchmarking Report.  The 2012 version released Tuesday includes 125 pharmaceutical and biotechnology professionals and their experiences with dozens of small, mid-size, and large CROs offering Phase II/III … Continued

ISR Report Measures Impact of Sunshine Act on Physician, Drug Manufacturer Interactions

Informing the drug development and commercialization industry Cary, N.C. – February 26, 2012 – Industry Standard Research (ISR) today announced the release of a new pharmaceutical market research report entitled “Sunshine Act: Pharma Impact – Changes in US Physician Behavior,” which quantifies the impact the adoption of the Sunshine Act will have on physicians’ interactions … Continued

ISR Expands Biosimilar Library with Two New Reports

Informing the Drug Development and Commercialization Industry Cary, N.C. – January 31, 2012 – Industry Standard Research (ISR) today announced the release of two new reports focused on the biosimilar industry. “US Payers and Biosimilar Formulary Placement” and “Biosimilars: A View from the Pharmacy” expand the base of knowledge regarding biosimilar market dynamics.  These reports … Continued

ISR: US Payers Indicate Comparative Effectiveness Research Gaining Importance

Informing the Drug Development and Commercialization Industry Cary, N.C. – January 17, 2012 – Industry Standard Research (ISR) today announced the release of a new report focused on the impact comparative effectiveness research (CER) is and will have on formulary placement . “US Payers: Comparative Effectiveness Research and formulary decision-making” looks at how US payers … Continued

New ISR Research Shows Some Prescribers Want More – Not Less – Drug Detailing

Cary, N.C. – January 11, 2012 – Industry Standard Research (ISR) today announced the availability of a new report titled”Electronic vs. In-person Detailing: A head-to-head comparison of Volume, Time, Value and Outcomes” that captures and compares product detail experiences from 118 Cardiologists, Oncologists, Family Practitioners, and Allergy / Immunologists. “The commonly held wisdom from both … Continued

New ISR Report Indicates Sponsors Prefer Specialty Providers for Imaging Services

Cary, N.C. – January 4, 2012 – Industry Standard Research (ISR) today announced the release of a new report titled “Clinical Imaging Market Dynamics and Service Provider Performance” in which 36 pharmaceutical sponsor decision-makers provide their usage, insights, and forecasts regarding the clinical imaging market by rating 98 service provider encounters. “The clinical imaging market … Continued

ISR’s New Report Profiles ECG Service Provider Performance

Informing the Drug Development and Commercialization Industry Cary, N.C. – December 13, 2011 – Industry Standard Research (ISR) today announced the release of a new report titled “Cardiac Safety / ECG Market Dynamics and Service Provider Performance” in which 79 pharmaceutical sponsor decision-makers provide their insights and forecasts regarding the ECG market by rating 286 … Continued

Research Profiles Industry’s Post-marketing Safety Conduct and Outsourcing

Cary, N.C. – September 19, 2011 – Industry Standard Research (ISR) today announced the release of an important piece of research, this one profiling the post-marketing safety industry. ISR’s new “Post-marketing Safety Market Overview and Outlook” report provides pharmaceutical companies and service providers with much needed data on the under served post-marketing safety marketplace. Compiled … Continued

Pharmacists Speak Out on Issue of Patient Adherence and Compliance

Cary, N.C. – September 13, 2011 – Industry Standard Research (ISR) today announced the release of a new report titled “Improving Adherence and Compliance: The Pharmacist’s View” in which 86 US-based retail (non-hospital based) pharmacists provided significant insights on the issues surrounding patient adherence and compliance. “When you talk about adherence and compliance, you must … Continued

New Research Profiles the State of the Phase I Market

Cary, N.C. – August 16, 2011 – Industry Standard Research (ISR) today announced the release of their “2011 Phase I Market Overview and Outlook” report, in which 104 pharmaceutical decision makers responsible for Phase I activities provide valuable insight into market size, growth and decline in the number of studies over the next 3 years, … Continued

Profiles of 18 Domestic Chinese Pharmaceutical Companies Point to Opportunities

Cary, N.C. – June 9, 2011 – Industry Standard Research (ISR) today announced the launch of a new and substantial research report titled “Domestic Chinese Pharmaceutical Companies: Competitor, Complementor, or Catalyst” This report profiles 18 of the largest and fastest growing domestic Chinese pharmaceutical companies by examining their corporate structure, current products, therapeutic areas of … Continued

New Research Projects Remote Clinical Monitoring to Double in the Next 4 Years

Cary, N.C. – February 8, 2011 – Industry Standard Research (ISR) today announced the launch of two new and substantial research reports titled “The Future of Clinical Monitoring” and “Clinical Development Staff Quality and Resourcing Models“. “It seems that every week brings the announcement of another merger or acquisition between biopharma companies or between CROs. … Continued

New Research Profiles the Site Coordinator’s Role in Clinical Trials Success

Cary, N.C. – November 15, 2010 – Industry Standard Research (ISR) today announced the launch of a new and substantial research report titled “The Voice of the Site Coordinator.” This report presents data and analysis from 124 interviews with Study / Site Coordinators from the US, Europe, Latin America, and Asia. “Most professionals in the … Continued

New Research Profiles the State of Biomarkers in Product Development

Cary, N.C. – June 28, 2010 – Industry Standard Research (ISR) today announced the release of The State of Biomarkers in Drug Development report. 44 pharmaceutical and biotechnology professionals provided their strategies, insights, and predictions in this snapshot of a rapidly evolving market. In total, 37 significant pharma and biotech companies contributed to this endeavor. … Continued

New Research Shows Small and Mid-Size CROs Inspire Greater Customer Loyalty

Cary, N.C. – April 19, 2010 – Industry Standard Research (ISR Reports) today announced the launch of the 2010 Edition of the CRO Quality Benchmarking Report. 150 pharmaceutical and biotechnology professionals provided their experiences with dozens of small, mid-size and large CROs in this “Consumer Reports”-style analysis of the industry. In total, data were collected … Continued

New Research Identifies UBC as the Leader in Late Phase Service Quality

Cary, N.C. – March 17, 2010 – Industry Standard Research (ISR Reports) today announced the launch of a new and substantial research report titled Late Phase Market Dynamics. This report presents data and analysis from 149 interviews with decision makers from 95 unique pharmaceutical and biotechnology companies around the world. “While the large, multi-service brands … Continued